ScoreWhy is Emcure Pharmaceuticals Ltd ?
1
High Management Efficiency with a high ROCE of 21.37%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.69 times
3
Poor long term growth as Operating profit has grown by an annual rate 8.80% of over the last 5 years
4
The company has declared Positive results for the last 5 consecutive quarters
- DPS(Y) Highest at Rs 3.00
- NET SALES(Q) Highest at Rs 2,269.82 cr
- PBDIT(Q) Highest at Rs 475.47 cr.
5
With ROCE of 21.4, it has a Expensive valuation with a 4.8 Enterprise value to Capital Employed
- Over the past year, while the stock has generated a return of 18.69%, its profits have risen by 36%
6
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 2.03% over the previous quarter and collectively hold 9.69% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
7
Market Beating Performance
- The stock has generated a return of 18.69% in the last 1 year, much higher than market (BSE500) returns of 8.47%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Emcure Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Emcure Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Emcure Pharma
18.98%
0.50
37.73%
Sensex
7.88%
0.70
11.23%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.90%
EBIT Growth (5y)
8.80%
EBIT to Interest (avg)
6.91
Debt to EBITDA (avg)
1.10
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
1.28
Tax Ratio
27.01%
Dividend Payout Ratio
0
Pledged Shares
0.04%
Institutional Holding
9.69%
ROCE (avg)
18.86%
ROE (avg)
16.94%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
34
Industry P/E
33
Price to Book Value
5.72
EV to EBIT
22.48
EV to EBITDA
17.08
EV to Capital Employed
4.80
EV to Sales
3.35
PEG Ratio
NA
Dividend Yield
0.21%
ROCE (Latest)
21.37%
ROE (Latest)
16.94%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
Bullish
OBV
Mildly Bullish
Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
DPS(Y)
Highest at Rs 3.00
NET SALES(Q)
Highest at Rs 2,269.82 cr
PBDIT(Q)
Highest at Rs 475.47 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 20.95%
PBT LESS OI(Q)
Highest at Rs 338.30 cr.
PAT(Q)
At Rs 243.46 cr has Grown at 29.0% (vs previous 4Q average
EPS(Q)
Highest at Rs 12.84
-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Emcure Pharma
Net Sales - Quarterly
Highest at Rs 2,269.82 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 475.47 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 20.95%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 338.30 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 338.30 cr has Grown at 31.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 257.01 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 243.46 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 243.46 cr has Grown at 29.0% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 188.66 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 12.84
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Dividend per Share (DPS) - Annually
Highest at Rs 3.00
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
